(Reuters) - Acura Pharmaceuticals Inc said the U.S. Food and Drug Administration (FDA) indicated that the company may have to conduct an additional study to determine the abuse-deterrent capability of its experimental painkiller treatment. The FDA in May said data was insufficient to support the company's claim that the drug could not be abused by snorting. Acura's drug, which contains common painkillers hydrocodone bitartrate and acetaminophen, is designed to cause a burning sensation when snorted or form a gelatinous mixture when dissolved for injecting. The FDA in December 2013 agreed to review the results of the failed mid-stage trial. via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment